Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board

Cellectar Biosciences, Inc.

Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.
Loren enters consulting agreement: $15,000/quarter for one year, plus 15,000 stock option grant.
Andrew Gu appointed as Class III director on May 18, 2026, selected by Nantahala Capital Management.
Gu is an analyst at Nantahala, focuses on biotech; he joins the Audit Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stefan D. Loren

Class III Director

CLRB · Cellectar Biosciences, Inc.

Filed: May 18, 2026 20:15 UTC

On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.

Appointed

Andrew Gu

Class III Director

CLRB · Cellectar Biosciences, Inc.

Effective: 2026-05-18
Filed: May 18, 2026 20:15 UTC

On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.

Source: SEC EDGAR

accession 0001104659-26-063202

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.